Phase 1/2Not yet recruiting
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy
Multi-center, Phase 1b/2 Clinical Study of an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy (C-CAR168) for the Treatment of Progressive Multiple Sclerosis Refractory to Standard Therapy
- Sponsor
- AbelZeta Inc. (Industry)
- Enrollment
- 119 planned
- Conditions
- Multiple Sclerosis; Primary Progressive Multiple Sclerosis; Secondary Progress Multiple Sclerosis (SPMS); Primary Progressive Multiple Sclerosis (PPMS); MS; MS (Multiple Sclerosis); Neuro-Degenerative Disease; Neuro-Degenerative Diseases; Autoimmune
- Interventions
- C-CAR168
- Ages
- adults
- Registry
- NCT07825389
Full record on ClinicalTrials.gov
From the registry
This is a global, multicenter, Phase 1b/2 study evaluating the safety and efficacy of C-CAR168, an autologous anti-CD20/BCMA chimeric antigen receptor T-cell therapy, in participants with progressive multiple sclerosis refractory to standard-of-care therapy. The study includes participants with secondary progressive multiple sclerosis (SPMS) and primary progressive multiple sclerosis (PPMS).
Primary outcomes
- Incidence and Severity of Treatment-Emergent Adverse Events
- Proportion of Participants With 6-Month Composite Confirmed Disability Progression (6m-cCDP) Through Month 12
History
Primary completion expected
Expected to start
Last registry update
Registered